Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering
This study identifies a post-infusion metabolic shift in CAR T-cells from glycolysis to amino acid-driven oxidative phosphorylation as a critical determinant of efficacy, revealing that amino acid depletion in patients limits T-cell function and demonstrating that engineering CAR T-cells to overexpress specific amino acid transporters (SLC1A5, SLC7A1, SLC38A9) enhances their persistence and anti-leukemic activity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human immune system is a vast, internal defense network, and among its most specialized soldiers are T-cells. These cells patrol the body, ready to recognize and destroy invaders or diseased cells. In recent years, doctors have learned to harness this power by taking a patient's own T-cells, reprogramming them in a laboratory to better hunt down cancer, and then infusing them back into the patient. This treatment, known as CAR T-cell therapy, has saved lives, particularly in children with certain types of blood cancer. However, the treatment does not work for everyone. Sometimes the engineered cells lose their strength or disappear too quickly after being put back into the body. To make the therapy more reliable, scientists need to understand exactly how these cells survive and function inside a living human, a place that is very different from the nutrient-rich dishes they grow in during manufacturing.
A team of researchers at the National Institutes of Health and collaborating institutions has taken a close look at this problem by studying the internal energy systems of these cancer-fighting cells. They discovered that once these cells enter a patient's body, they undergo a dramatic shift in how they generate power. Before infusion, the cells rely heavily on sugar for energy, much like a car running on gasoline. But once inside the patient, they switch to a different fuel source: amino acids, which are the building blocks of proteins. This new way of working allows the cells to sustain their attack for longer periods. The researchers also found that the body's own reaction to the cancer treatment creates a harsh environment where these amino acids become scarce. By understanding this struggle, the team engineered a new version of the therapy that helps the cells grab onto these scarce nutrients more effectively, allowing them to fight cancer more powerfully in laboratory tests.
The journey of a CAR T-cell begins in a laboratory, where scientists grow them in conditions filled with plenty of nutrients and oxygen. In this comfortable environment, the cells run on sugar, a process known as glycolysis. This is efficient for rapid growth in a dish. However, the moment these cells are infused into a patient, the environment changes drastically. The patient's body is often under stress from the cancer and the chemotherapy used to prepare for the treatment. To see what happens next, the researchers developed a new way to measure the energy habits of individual cells taken from patients. They used a method that tracks how much protein the cells are making, which serves as a reliable indicator of their overall energy and activity levels.
When they analyzed cells taken from patients a week or two after infusion, they found a surprising transformation. The cells had largely abandoned their sugar-based metabolism. Instead, they had switched to a more complex system that relies on oxygen and amino acids to generate energy. This shift was not random; it was a consistent pattern seen across different patients and different types of engineered cells. The researchers observed that the cells which successfully expanded and cleared the cancer were the ones that had made this switch most effectively. Specifically, a subset of cells that looked like "stem cells"—young, versatile cells capable of long-term survival—were the ones most dependent on this new amino acid-fueled energy system. These cells were found in higher numbers in patients who achieved a complete remission, suggesting that this metabolic shift is a key factor in a successful treatment.
The study also revealed why this switch is so difficult for the cells to maintain. As the engineered T-cells began to multiply and fight the cancer, they triggered a massive immune response in the patient's body, often causing a condition called cytokine release syndrome. This is a state of intense inflammation where the body releases a flood of signaling proteins. The researchers measured the blood of patients during this peak inflammatory phase and found that the levels of several crucial amino acids, particularly glutamine and arginine, had dropped to very low levels. The inflammation had essentially stripped the bloodstream of the very fuel the T-cells needed to survive. It was a race against time: the cells needed amino acids to keep their engines running, but the body's own reaction to the therapy was depleting those supplies.
To solve this problem, the researchers looked at the genetic instructions of the cells that were doing the best job. They found that the successful cells had turned up the volume on specific genes that act as doors or transporters on the cell surface. These transporters are specialized proteins that pull amino acids from the surrounding environment into the cell. The researchers identified three specific transporters that were particularly effective at this job. They then engineered new CAR T-cells to carry extra copies of these transporters, essentially giving the cells larger nets to catch the scarce nutrients.
When they tested these "armored" cells in the laboratory, the results were clear. Under normal conditions, the new cells performed similarly to the standard ones. But when the researchers created a stressful environment with very low levels of amino acids—mimicking the harsh conditions inside a patient—the armored cells thrived. They were able to maintain their energy production and continue killing cancer cells, while the standard cells struggled and lost their effectiveness. In tests using mice with leukemia, the armored cells cleared the cancer faster and more completely than the unmodified cells, even when given in smaller numbers.
This work provides a new blueprint for improving cancer immunotherapy. It shows that the success of these treatments depends not just on the design of the cell itself, but on how well it can adapt to the metabolic challenges of the human body. By recognizing that amino acids are the critical fuel for long-term survival, and that the body's inflammatory response creates a shortage of this fuel, scientists can now engineer cells that are better equipped to handle the stress. The study suggests that future therapies could be designed to be more resilient, ensuring that the cells have the resources they need to finish the job of eliminating the cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.